Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 23, 2007BloodOpen Access

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

View Full Paper
Ask AI
Bookmark
Share

Authors

Hagop M. KantarjianHagop M. KantarjianThe University of Texas MD Anderson Cancer CenterFGFrancis J. GilesUniversity College DublinNGNorbert GattermannGoethe University Frankfurt

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kantarjian et al. (2007) studied this question.

synapsesocial.com/papers/6a15a5f29b87f33fc69fbb2ehttps://doi.org/10.1182/blood-2007-03-080689
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chronic Myeloid Leukemia1999 · 1,637 citations
  2. 2Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis2004 · 178 citations
  3. 3Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy2006 · 612 citations
  4. 4Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia2006 · 3,516 citations
  5. 5High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia2003 · 394 citations